Large genomic analysis highlights COVID-19 risk factors

An international collaboration uncovers several genetic markers associated with SARS-CoV-2 infection or COVID-19 severity.

In March of 2020, thousands of scientists around the world united to answer a pressing and complex question: what genetic factors influence why some COVID-19 patients develop severe, life-threatening disease requiring hospitalization, while others escape with mild symptoms or none at all?

A comprehensive summary of their findings to date, published in Nature, reveals 13 loci, or locations in the human genome, that are strongly associated with infection or severe COVID-19. These results come from one of the largest genome-wide association studies ever performed, which includes nearly 50,000 COVID-19 patients and two million controls. 

The work also involved members of the Cluster of Excellence “Precision Medicine in Chronic Inflammation” (PMI) from the Institute of Clinical Molecular Biology (IKMB) at Kiel University (CAU) and Schleswig-Holstein University Hospital (UKSH), Kiel Campus. The team led by Professor Andre Franke, director of the IKMB and steering committee member in the Cluster PMI, had already identified the first genetic risk factors early in the pandemic, in spring 2020, and published them in the renowned New England Journal of Medicine (NEJM). Statistical data from that work informed the new global study.

"We were able to contribute a particularly large amount of data on patients from our previous work, and our study is among those with the highest number of cases. We are pleased that we were able to contribute to this large project," Franke says. "At the same time, the work that has now been published was able to clearly confirm the risk genes we found."

Cooperation of enormous scale

The work was done by the COVID-19 Host Genomics Initiative. The initiative has grown to be one of the most extensive collaborations in human genetics and currently includes more than 3,500 authors and 61 studies from 25 countries. To do their analysis, the consortium pooled clinical and genetic data from the nearly 50,000 patients in their study who tested positive for the virus, and 2 million controls across numerous biobanks, clinical studies, and direct-to-consumer genetic companies. Because of the large amount of data pouring in from around the world, the scientists were able to produce statistically robust analyses far more quickly, and from a greater diversity of populations, than any one group could have on its own.

"In total, hundreds of studies worldwide were included in this meta-study, which has now been published, so the significance of this work is particularly high," Franke emphasizes. "It was only possible because so many researchers collaborated so openly and shared data transparently. This has not happened on this scale before and is an excellent example of how science can work quickly and efficiently," Franke continues.

Study confirms Kiel results

The Kiel team, in collaboration with other research groups, had identified two specific areas in the genome in spring 2020 that increase the risk of SARS-CoV-2 infection and severe COVID-19 progression: First, they found an abnormality in the blood group trait gene: people with blood group A are thus at higher risk for infection than people with other blood groups. People with blood group 0, on the other hand, are better protected from COVID-19 disease. "The work now available has clearly confirmed, with an even much larger amount of data, that genetic variation in the blood group gene influences the risk of infection," summarizes Professor David Ellinghaus, scientist at the IKMB and member of PMI.

In addition, Franke's team had found a second region in the genome in the previous work that influences both the general susceptibility to infection and the severity of a COVID-19 disease - namely on chromosome 3. "This locus even proved to be the most statistically significant of all 13 risk loci in the study now available and occurs constantly in the studies included," emphasizes Dr. Frauke Degenhardt, biostatistician at the IKMB. "Thus, the change in this gene region probably plays a particularly important role with regard to susceptibility to infection and to the severity of COVID-19 disease," Degenhardt adds. 

Basis for therapeutic approaches

"Building on the risk genes described, it is now possible to analyze in more detail which functions are hidden behind them. What do the genetic changes in these areas lead to, what do they do in the body? With a more precise understanding of these mechanisms, it may be possible to find targets for therapy against COVID-19," Franke explains.

The researchers will continue to study more data as they come in and update their results through the “Matters Arising” format at Nature. They will begin to study what differentiates “long-haulers”, or patients whose COVID-19 symptoms persist for months, from others, and continue to identify additional loci associated with infection and severe disease.

Kleine Probenchips werden für die Analyse vorbereitet
© Oliver Franke, IKMB Uni Kiel

Sample preparation for genetic analysis

Original publication:

The COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. Online July 8, 2021.


Scientific Contact:

Dr. Frauke Degenhardt
Institute of Clinical Molecular Biology , Kiel University and UKSH
+49 431-500 15 147


About the Cluster of Excellence PMI

The Cluster of Excellence "Precision Medicine in Chronic Inflammation" (PMI) is being funded from 2019 to 2025 through the German Excellence Strategy (ExStra). It succeeds the "Inflammation at Interfaces” Cluster, which was already funded in two periods of the Excellence Initiative (2007-2018). Around 300 members from eight institutions at four locations are involved: Kiel (Kiel University, University Medical Center Schleswig-Holstein (UKSH), Muthesius University of Fine Arts and Design, Kiel Institute for the World Economy (IfW), Leibniz Institute for Science and Mathematics Education (IPN)), Lübeck (University of Lübeck, University Medical Center Schleswig-Holstein (UKSH)), Plön (Max Planck Institute for Evolutionary Biology) and Borstel (Research Center Borstel - Leibniz Lung Center).

The goal is to translate interdisciplinary research findings on chronic inflammatory diseases of barrier organs to healthcare more intensively, as well as to fulfil previously unsatisfied needs of the patients. Three points are important in the context of successful treatment, and are therefore at the heart of PMI research: the early detection of chronic inflammatory diseases, the prediction of disease progression and complications, and the prediction of individual responses to treatment.

Press office

Frederike Buhse
Public Relations, Excellence Cluster PMI

Cluster of Excellence "Precision Medicine in Chronic Inflammation"
Scientific Office
Head: Dr. habil. Susanne Holstein Postal
Christian-Albrechts-Platz 4, 24118 Kiel, Germany
Contact: Sonja Petermann
 +49 (0)431 880-4850, fax: +49 (0)431 880-4894
Twitter: PMI @medinflame